GlassScriptPhysician profile
Sayyid Simte Raza
NPI 1336176486
$1,137.71
in general payments reported to CMS, 2019-2025
29 companies · $70.73 in 2025
The $70.73 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.46 · 2020: $256 · 2021: $244 · 2022: $143 · 2023: $195 · 2024: $187 · 2025: $70.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $235.52 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $82.23 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $69.38 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $63.92 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $53.92 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $46.69 | 2021-2022 | |
| Ucb, INC. | $46.19 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $43.16 | 2023-2024 | Rexulti |
| Pfizer INC. | $41.96 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $39.49 | 2023 | Spravato |
| Corcept Therapeutics | $33.12 | 2020 | |
| Dexcom, INC. | $32.48 | 2020-2021 | |
| Amgen INC. | $31.90 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $31.39 | 2022-2023 | Livalo, Seglentis |
| Sumitomo Pharma America, INC. | $31.28 | 2023 | Gemtesa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.23 | 2021-2022 | |
| Abbvie INC. | $26.08 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.89 | 2020 | |
| Biogen, INC. | $23.39 | 2021 | |
| Sunovion Pharmaceuticals INC. | $20.00 | 2022 | |
| Lilly USA, LLC | $19.76 | 2021 | |
| Exact Sciences Corporation | $18.15 | 2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $17.00 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $13.79 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $13.72 | 2024 | |
| Eisai INC. | $13.59 | 2021 | |
| Philips North America LLC | $12.87 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.35 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayyid Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.